Literature DB >> 27185371

Depletion of FOXM1 via MET Targeting Underlies Establishment of a DNA Damage-Induced Senescence Program in Gastric Cancer.

Paola Francica1,2, Lluís Nisa1,2, Daniel M Aebersold1,2, Rupert Langer3, Friedhelm Bladt4, Andree Blaukat4, Deborah Stroka2,5, María Rodríguez Martínez6, Yitzhak Zimmer1,2, Michaela Medová7,2.   

Abstract

PURPOSE: Deregulated signaling via the MET receptor tyrosine kinase is abundant in gastric tumors, with up to 80% of cases displaying aberrant MET expression. A growing body of evidence suggests MET as a potential target for tumor radiosensitization. EXPERIMENTAL
DESIGN: Cellular proliferation and DNA damage-induced senescence were studied in a panel of MET-overexpressing human gastric cancer cell lines as well as in xenograft models after MET inhibition and/or ionizing radiation. Pathways activation and protein expression were assessed by immunoblotting and immunohistochemistry. Tumor tissue microarrays (91 gastric cancer patients) were generated and copy number alteration (178 patients) and gene expression (373 patients) data available at The Cancer Genome Atlas were analyzed to assess the coalterations of MET and FOXM1.
RESULTS: MET targeting administered before ionizing radiation instigates DNA damage-induced senescence (∼80%, P < 0.001) rather than cell death. MET inhibition-associated senescence is linked to the blockade of MAPK pathway, correlates with downregulation of FOXM1, and can be abrogated (11.8% vs. 95.3%, P < 0.001) by ectopic expression of FOXM1 in the corresponding gastric tumor cells. Cells with ectopic FOXM1 expression demonstrate considerable (∼20%, P < 0.001) growth advantage despite MET targeting, suggesting a novel clinically relevant resistance mechanism to MET inhibition as the copresence of both MET and FOXM1 protein (33%) and mRNA (30%) overexpression as well as gene amplification (24,7%) are common in patients with gastric cancer.
CONCLUSIONS: FOXM1, a negative regulator of senescence, has been identified as a key downstream effector and potential clinical biomarker that mediates MET signaling following infliction of DNA damage in gastric tumors. Clin Cancer Res; 22(21); 5322-36. ©2016 AACR. ©2016 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27185371     DOI: 10.1158/1078-0432.CCR-15-2987

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  13 in total

1.  TCPOBOP-Induced Hepatomegaly and Hepatocyte Proliferation are Attenuated by Combined Disruption of MET and EGFR Signaling.

Authors:  Bharat Bhushan; John W Stoops; Wendy M Mars; Anne Orr; William C Bowen; Shirish Paranjpe; George K Michalopoulos
Journal:  Hepatology       Date:  2018-12-31       Impact factor: 17.425

2.  Identification of a MET-eIF4G1 translational regulation axis that controls HIF-1α levels under hypoxia.

Authors:  Astrid A Glück; Eleonora Orlando; Dominic Leiser; Michaela Poliaková; Lluís Nisa; Aurélie Quintin; Jacopo Gavini; Deborah M Stroka; Sabina Berezowska; Lukas Bubendorf; Andree Blaukat; Daniel M Aebersold; Michaela Medová; Yitzhak Zimmer
Journal:  Oncogene       Date:  2018-05-02       Impact factor: 9.867

Review 3.  Prognostic value of FOXM1 in solid tumors: a systematic review and meta-analysis.

Authors:  Lijun Li; Dang Wu; Qun Yu; Lingdi Li; Pin Wu
Journal:  Oncotarget       Date:  2017-05-09

4.  FOXM1 evokes 5-fluorouracil resistance in colorectal cancer depending on ABCC10.

Authors:  Tao Xie; Jian Geng; Ye Wang; Liya Wang; Mengxi Huang; Jing Chen; Kai Zhang; Lijun Xue; Xiaobei Liu; Xiaobei Mao; Yanan Chen; Qian Wang; Tingting Dai; Lili Ren; Hongju Yu; Rui Wang; Longbang Chen; Cheng Chen; Xiaoyuan Chu
Journal:  Oncotarget       Date:  2017-01-31

5.  PARI functions as a new transcriptional target of FOXM1 involved in gastric cancer development.

Authors:  Yi Zhang; Xiaojuan Ye; Lizhi Chen; Qiong Wu; Yong Gao; Yandong Li
Journal:  Int J Biol Sci       Date:  2018-04-05       Impact factor: 6.580

6.  FOXM1 promotes hepatocellular carcinoma progression by regulating KIF4A expression.

Authors:  Guohui Hu; Zhengwei Yan; Cheng Zhang; Minzhang Cheng; Yehong Yan; Yiting Wang; Libin Deng; Quqin Lu; Shiwen Luo
Journal:  J Exp Clin Cancer Res       Date:  2019-05-09

7.  Overexpression of FoxM1 predicts poor prognosis of intrahepatic cholangiocarcinoma.

Authors:  Lingyun Liu; Jian Wu; Yu Guo; Wenxuan Xie; Bin Chen; Yi Zhang; Shaoqiang Li; Yunpeng Hua; Baogang Peng; Shunli Shen
Journal:  Aging (Albany NY)       Date:  2018-12-21       Impact factor: 5.682

8.  LECT 2 Antagonizes FOXM1 Signaling via Inhibiting MET to Retard PDAC Progression.

Authors:  Xin Li; Pingping Lin; Ye Tao; Xin Jiang; Ting Li; Yunshan Wang; Chenjing Wang; Yu Cao
Journal:  Front Cell Dev Biol       Date:  2021-04-15

9.  Effects of forkhead box protein M1 on trophoblast invasion and its role in preeclampsia development.

Authors:  Xuena Cui; Jin'e Xu; Yuzhi Ji; Xiuhong Song; Junhuan Wang; Lijuan Zhang; Shengmei Yang; Yuanhua Ye
Journal:  Exp Ther Med       Date:  2018-05-18       Impact factor: 2.447

10.  Deciphering MET-dependent modulation of global cellular responses to DNA damage by quantitative phosphoproteomics.

Authors:  Ariel Bensimon; Jonas P Koch; Paola Francica; Selina M Roth; Rahel Riedo; Astrid A Glück; Eleonora Orlando; Andree Blaukat; Daniel M Aebersold; Yitzhak Zimmer; Ruedi Aebersold; Michaela Medová
Journal:  Mol Oncol       Date:  2020-05-13       Impact factor: 6.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.